PRIMARY STUDY
β-caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner.
Key Findings: BCP may be an excellent therapeutic agent to prevent cisplatin-induced nephrotoxicity through a CB2 receptor dependent pathway. Given the excellent safety profile of BCP in humans it has tremendous therapeutic potential in multitude of diseases associated with inflammation and oxidative stress.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): Switzerland, United States
Year of Pub: 2013
Cannabinoids Studied:
Terpenes Studied: ß-Caryophyllene
Receptors Studied: CB2
Ligands Studied: Anti-inflammatory cytokines, Pro-inflammatory cytokines
Dosage: β-caryophyllene (1, 3 and 10 mg/kg, i.p.) daily, starting 2 hours before the cisplatin administration
Link to study
